No Data
Here's the Major Earnings Before the Open Tomorrow
US CDC Reports 36 H5 Bird Flu Cases In U.S. Since April; Six Cases In Washington Poultry Workers Confirmed Last Week; No Person-To-Person Spread Detected; Public Risk Remains Low But Higher For Those Exposed To Infected Animals; 15 Cases Linked To...
GSK Q3 2024 Earnings Preview
Unusual Options Activity: AMKR, GEHC and Others Attract Market Bets, AMKR V/OI Ratio Reaches 830.8
GSK once again came to China to acquire innovative drugs! Signed a $0.85 billion agreement to expand the lupus pipeline.
① The total value of this trade can reach up to $0.85 billion, with an initial payment of $0.3 billion; ② This acquisition will further expand GSK's own immune disease treatment pipeline; ③ With the global recognition of China Meheco Group's R&D capabilities, such trades have been rapidly increasing in recent years.
GSK to Start Phase I Trial in Lupus in 2025
